Search Results - "Parker, Terri L"

Leukaemic vasculitis with myelodysplastic syndrome by Odell, Ian D, Dr, Zeidan, Amer M, MB, Parker, Terri L, MD, Colegio, Oscar R, PhD, Subtil, Antonio, MD

“…Bone marrow biopsy specimen showed increased early myeloid forms with 5% CD34+ myeloblasts with abnormal localisation of immature precursors and…”
Get full text

Whole-exome sequencing in evaluation of patients with venous thromboembolism by Lee, Eun-Ju, Dykas, Daniel J., Leavitt, Andrew D., Camire, Rodney M., Ebberink, Eduard, García de Frutos, Pablo, Gnanasambandan, Kavitha, Gu, Sean X., Huntington, James A., Lentz, Steven R., Mertens, Koen, Parish, Christopher R., Rezaie, Alireza R., Sayeski, Peter P., Cromwell, Caroline, Bar, Noffar, Halene, Stephanie, Neparidze, Natalia, Parker, Terri L., Burns, Adrienne J., Dumont, Anne, Yao, Xiaopan, Chaar, Cassius Iyad Ochoa, Connors, Jean M., Bale, Allen E., Lee, Alfred Ian

“…Genetics play a significant role in venous thromboembolism (VTE), yet current clinical laboratory-based testing identifies a known heritable thrombophilia…”
Get full text

Peripheral Blasts in a Patient Receiving Chemotherapy by Kshattry, Sabin, Parker, Terri L, Huntington, Scott F

“…An older patient with stage II bladder carcinoma presented with 1 week of fatigue and 2 days of dyspnea on exertion. He was receiving carboplatin/gemcitabine…”
Get full text

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial by Kumar, Shaji K, Jacobus, Susanna J, Cohen, Adam D, Weiss, Matthias, Callander, Natalie, Singh, Avina K, Parker, Terri L, Menter, Alexander, Yang, Xuezhong, Parsons, Benjamin, Kumar, Pankaj, Kapoor, Prashant, Rosenberg, Aaron, Zonder, Jeffrey A, Faber, Edward, Lonial, Sagar, Anderson, Kenneth C, Richardson, Paul G, Orlowski, Robert Z, Wagner, Lynne I, Rajkumar, S Vincent

“…Bortezomib, lenalidomide, and dexamethasone (VRd) is a standard therapy for newly diagnosed multiple myeloma. Carfilzomib, a next-generation proteasome…”
Get full text

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma by Chari, Ajai, Vogl, Dan T, Gavriatopoulou, Maria, Nooka, Ajay K, Yee, Andrew J, Huff, Carol A, Moreau, Philippe, Dingli, David, Cole, Craig, Lonial, Sagar, Dimopoulos, Meletios, Stewart, A. Keith, Richter, Joshua, Vij, Ravi, Tuchman, Sascha, Raab, Marc S, Weisel, Katja C, Delforge, Michel, Cornell, Robert F, Kaminetzky, David, Hoffman, James E, Costa, Luciano J, Parker, Terri L, Levy, Moshe, Schreder, Martin, Meuleman, Nathalie, Frenzel, Laurent, Mohty, Mohamad, Choquet, Sylvain, Schiller, Gary, Comenzo, Raymond L, Engelhardt, Monika, Illmer, Thomas, Vlummens, Philip, Doyen, Chantal, Facon, Thierry, Karlin, Lionel, Perrot, Aurore, Podar, Klaus, Kauffman, Michael G, Shacham, Sharon, Li, Lingling, Tang, Shijie, Picklesimer, Carla, Saint-Martin, Jean-Richard, Crochiere, Marsha, Chang, Hua, Parekh, Samir, Landesman, Yosef, Shah, Jatin, Richardson, Paul G, Jagannath, Sundar

“…Selinexor, a drug that inhibits nuclear export of tumor suppressor proteins, was tested in a phase 2 trial involving patients with myeloma whose disease had…”
Get full text

Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma by Patel, Kishan K, Giri, Smith, Parker, Terri L, Bar, Noffar, Neparidze, Natalia, Huntington, Scott F

“…The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in…”
Get full text

Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis by Muradashvili, Tinatin, Yu, Mansen, Browning, Sabrina L., Bar, Noffar, Gorshein, Elan, Parker, Terri L., Neparidze, Natalia

Get full text

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma by Vogl, Dan T, Dingli, David, Cornell, Robert Frank, Huff, Carol Ann, Jagannath, Sundar, Bhutani, Divaya, Zonder, Jeffrey, Baz, Rachid, Nooka, Ajay, Richter, Joshua, Cole, Craig, Vij, Ravi, Jakubowiak, Andrzej, Abonour, Rafat, Schiller, Gary, Parker, Terri L, Costa, Luciano J, Kaminetzky, David, Hoffman, James E, Yee, Andrew J, Chari, Ajai, Siegel, David, Fonseca, Rafael, Van Wier, Scott, Ahmann, Gregory, Lopez, Ilsel, Kauffman, Michael, Shacham, Sharon, Saint-Martin, Jean-Richard, Picklesimer, Carla D, Choe-Juliak, Cassandra, Stewart, A Keith

“…Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor…”
Get full text

Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate by Foss, Francine M., Parker, Terri L., Girardi, Michael, Li, Anlong

“…Peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) are rare, heterogeneous non-Hodgkin lymphomas with poor prognoses. Pralatrexate has…”
Get full text

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials by Gavriatopoulou, Maria, Chari, Ajai, Chen, Christine, Bahlis, Nizar, Vogl, Dan T., Jakubowiak, Andrzej, Dingli, David, Cornell, Robert F., Hofmeister, Craig C., Siegel, David, Berdeja, Jesus G., Reece, Donna, White, Darrell, Lentzsch, Suzanne, Gasparetto, Cristina, Huff, Carol Ann, Jagannath, Sundar, Baz, Rachid, Nooka, Ajay K., Richter, Joshua, Abonour, Rafat, Parker, Terri L., Yee, Andrew J., Moreau, Philippe, Lonial, Sagar, Tuchman, Sascha, Weisel, Katja C., Mohty, Mohamad, Choquet, Sylvain, Unger, T. J., Li, Kai, Chai, Yi, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Dimopoulos, Meletios Athanasios

“…Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side…”
Get full text

Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate by Foss, Francine M., Parker, Terri L., Girardi, Michael, Li, Anlong

Get full text

Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart by Bar, Noffar, Parker, Terri L, Dhodapkar, Madhav V

Get full text

Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer by Bar, Noffar, Costa, Federica, Das, Rituparna, Duffy, Alyssa, Samur, Mehmet, McCachren, Samuel, Gettinger, Scott N, Neparidze, Natalia, Parker, Terri L, Bailur, Jithendra Kini, Pendleton, Katherine, Bajpai, Richa, Zhang, Lin, Xu, Mina L, Anderson, Tara, Giuliani, Nicola, Nooka, Ajay, Cho, Hearn J, Raval, Aparna, Shanmugam, Mala, Dhodapkar, Kavita M, Dhodapkar, Madhav V

“…BACKGROUNDPD-1 and PD-L1 have been studied interchangeably in the clinic as checkpoints to reinvigorate T cells in diverse tumor types. Data for biologic…”
Get full text

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial by Kumar, Shaji, Jacobus, Susanna J., Cohen, Adam D., Weiss, Matthias, Callander, Natalie Scott, Singh, Avina A., Parker, Terri L., Menter, Alex R., Yang, Xuezhong, Parsons, Benjamin Marshall, Kumar, Pankaj, Kapoor, Prashant, Rosenberg, Aaron Seth, Zonder, Jeffrey A., Faber, Edward Anthony, Lonial, Sagar, Richardson, Paul G., Orlowski, Robert Z., Wagner, Lynne I., Rajkumar, S. Vincent

“…Abstract only LBA3 Background: Bortezomib (btz) combined with lenalidomide (len) and dexamethasone (dex) (VRd) is a standard initial therapy for NDMM…”
Get full text

Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial by Branagan, Andrew R., Duffy, Eamon, Albrecht, Randy A., Cooper, Dennis L., Seropian, Stuart, Parker, Terri L., Gan, Geliang, Li, Fangyong, Zelterman, Daniel, Boddupalli, Chandra Sekhar, Zhang, Lin, Verma, Rakesh, Ferencz, Thomas M., Dhodapkar, Madhav V.

“…The goal of the present study was to evaluate a novel prospective influenza vaccination strategy for patients with plasma cell disorders. Fifty-one patients…”
Get full text

Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias by Branagan, Andrew R., Duffy, Eamon, Gan, Geliang, Li, Fangyong, Foster, Connor, Verma, Rakesh, Zhang, Lin, Parker, Terri L., Seropian, Stuart, Cooper, Dennis L., Brandt, Debra, Kortmansky, Jeremy, Witt, Davit, Ferencz, Thomas M., Dhodapkar, Kavita M., Dhodapkar, Madhav V.

“…Patients with plasma cell dyscrasias (PCDs) experience an increased burden of influenza, and current practice of single-dose annual influenza vaccination…”
Get full text

Chronic lymphocytic leukemia: prognostic factors and impact on treatment by Parker, Terri L, Strout, Matthew P

“…Chronic lymphocytic leukemia (CLL) is a clonal malignancy of mature B cells that displays immense clinical heterogeneity as reflected by the observation that…”
Get more information

Clinical and serologic responses following a two dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial by Branagan, Andrew R., MD, Duffy, Eamon, Albrecht, Randy A., PhD, Cooper, Dennis L., MD, Seropian, Stuart, MD, Parker, Terri L., MD, Gan, Geliang, PhD, Li, Fangyong, MPH, Zelterman, Daniel, PhD, Boddupalli, Chandra Sekhar, PhD, Zhang, Lin, Verma, Rakesh, PhD, Ferencz, Thomas M., RPh, Dhodapkar, Madhav V., MD

“…Abstract Background Patients with multiple myeloma (MM) and other plasma cell disorders are highly susceptible to influenza infections, which are major causes…”
Get full text

I didn't even raise my hand: a mother's retrospective journey through end-of-life decisionmaking at the "threshold of viability" by Parker, Terri L

Get full text

Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma by Patel, Kishan, Parker, Terri L., Di, Mengyang, Bar, Noffar, Huntington, Scott F., Giri, Smith

“…Introduction: The phase III BOSTON trial reported that once-weekly therapy with selinexor, bortezomib, and dexamethasone (SVd) significantly prolonged…”
Get full text